Halozyme Therapeutics Inc logo

Halozyme Therapeutics Inc

$ 42.73 -0.6765 (-1.56%) 10:02 AM EST
P/E:
16.89
P/B:
20.07
Market Cap:
$ 5.89B
Enterprise V:
$ 6.93B
Volume:
83.69K
Avg Vol (2M):
1.51M
Also Trade In:
Volume:
83.69K
Market Cap $:
5.89B
PE Ratio:
16.89
Avg Vol (2-Month):
1.51M
Enterprise Value $:
6.93B
PB Ratio:
20.07
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Halozyme Therapeutics Inc
NAICS : 325414 SIC : 2836
11388 Sorrento Valley Road, San Diego, CA, USA, 92121
Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Name Current Vs Industry Vs History
Cash-To-Debt 0.17
Equity-to-Asset 0.17
Debt-to-Equity 4.25
Debt-to-EBITDA 4.85
Interest Coverage 27.89
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.38
Distress
Grey
Safe
Beneish M-Score 14.9
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 36.01
9-Day RSI 34.92
14-Day RSI 38.36
6-1 Month Momentum % 48.88
12-1 Month Momentum % 20.73

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.72
Quick Ratio 2.23
Cash Ratio 1.05
Days Inventory 254.42
Days Sales Outstanding 94.64
Days Payable 18.59

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 1.7

Financials (Next Earnings Date:2022-11-02 Est.)

HALO's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:HALO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 487.477
EPS (TTM) ($) 2.53
Beta 1.19
Volatility % 39.34
14-Day RSI 38.36
14-Day ATR ($) 1.962842
20-Day SMA ($) 46.8305
12-1 Month Momentum % 20.73
52-Week Range ($) 31.36 - 52.98
Shares Outstanding (Mil) 137.78

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Halozyme Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More